Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

Mukesh Ambani's Reliance Industries (RIL) offloaded 85 lakh shares of Asian Paints, India’s largest paint manufacturer, ...

The funds will be used to purchase outstanding optionally convertible debentures issued by the company’s subsidiary Biocon ...

During Tuesday’s trading session, shares of a global biopharmaceutical company engaged in the manufacturing of biotechnology products and research services are in focus, after the company launched a ...

Bengaluru-based Biocon Ltd. closes the window to list its arm, Biocon Biologics Ltd., as it raises Rs 4,500 crore to provide ...

Shares of Biocon Ltd., surged 1.3% on Tuesday after the company's board of directors approved the floor price for the share ...

Biocon informed that its board has approved the opening of the issue of qualified institutional placement (QIP) of equity shares with the floor price of Rs 340.20 per equity share.

The report highlights the top five sectors drawing the most capital: Consumer Products & Brands led with a 9.55% share, ...

The decision comes after receiving approvals from the Board of Directors in April and from shareholders through a postal ...

Several stocks will be in focus due to company announcements and other key updates. These include Tata Consultancy Services ...